Omega-3 fatty acids are protective against paclitaxel-induced peripheral neuropathy: a randomized double-blind placebo controlled trial
Ghoreishi Z, Esfahani A, Djazayeri A, Djalali M, Golestan B, Ayromlou H, Hashemzade S, Asghari Jafarabadi M, Montazeri V, Keshavarz SA, Darabi M
BMC cancer · 115 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
Según la declaración de financiación del texto completo.
Publicación
- Publicado
- 2012-08-15 · BMC Cancer · vol. 12 · número 1 · pág. 355
- Editorial
- BioMed Central
- Citado
- 171 citas · más que el 96% de estudios similares · 4.4× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 27 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY
- Áreas de investigación
- Cancer Treatment and Pharmacology · Chemotherapy-related skin toxicity · Pain Mechanisms and Treatments
- Palabras clave
- omega-3 fatty acids, paclitaxel, peripheral neuropathy, chemotherapy-induced peripheral neuropathy, breast cancer, neuroprotection, Total Neuropathy Score, electrophysiological assessment, quality of life
- MeSH
- humans, breast neoplasms, peripheral nervous system diseases, paclitaxel, fatty acids, omega-3, neuroprotective agents, antineoplastic agents, phytogenic, treatment outcome, neural conduction, dietary supplements, adult, middle aged, female
11 autores
- Zohreh Ghoreishi🇮🇷Tehran University of Medical Sciences
- Ali Esfahani🇮🇷Tabriz University of Medical Sciences
- Abolghasem Djazayeri🇮🇷Tehran University of Medical Sciences
- Mahmoud Djalali🇮🇷Tehran University of Medical Sciences
- B Golestan🇮🇷Tehran University of Medical Sciences
- Hormoz Ayromlou🇮🇷Tabriz University of Medical Sciences
- Shahriar Hashemzade🇮🇷Tabriz University of Medical Sciences
- Mohammad Asghari Jafarabadi🇮🇷Tabriz University of Medical Sciences; Tabriz Health Services Management Research Center
- Vahid Montazeri🇮🇷Tabriz University of Medical Sciences
- Seyed Ali Keshavarz🇮🇷 · autor de correspondenciaTehran University of Medical Sciences
- Masoud Darabi🇮🇷Tabriz University of Medical Sciences
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Axonal sensory peripheral neuropathy is the major dose-limiting side effect of paclitaxel.Omega-3 fatty acids have beneficial effects on neurological disorders from their effects on neurons cells and inhibition of the formation of proinflammatory cytokines involved in peripheral neuropathy.
Methods
This study was a randomized double blind placebo controlled trial to investigate the efficacy of omega-3 fatty acids in reducing incidence and severity of paclitaxel-induced peripheral neuropathy (PIPN). Eligible patients with breast cancer randomly assigned to take omega-3 fatty acid pearls, 640 mg t.i.d during chemotherapy with paclitaxel and one month after the end of the treatment or placebo. Clinical and electrophysiological studies were performed before the onset of chemotherapy and one month after cessation of therapy to evaluate PIPN based on "reduced Total Neuropathy Score".
Results
Twenty one patients (70%) of the group taking omega-3 fatty acid supplement (n = 30) did not develop PN while it was 40.7%( 11 patients) in the placebo group(n = 27). A significant difference was seen in PN incidence (OR = 0.3, .95% CI = (0.10-0.88), p = 0.029). There was a non-significant trend for differences of PIPN severity between the two study groups but the frequencies of PN in all scoring categories were higher in the placebo group (0.95% CI = (-2.06 -0.02), p = 0.054).
Conclusions
Omega-3 fatty acids may be an efficient neuroprotective agent for prophylaxis against PIPN. Patients with breast cancer have a longer disease free survival rate with the aid of therapeutical agents. Finding a way to solve the disabling effects of PIPN would significantly improve the patients' quality of life.
Trial registration
This trial was registered at ClinicalTrials.gov (NCT01049295).
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.